An expert discusses how albuminuria and declining estimated glomerular filtration rate (eGFR) serve as vital early biomarkers for kidney and cardiovascular health, stressing the importance of regular testing and early intervention to prevent disease progression and improve patient outcomes.
New findings reveal aflibercept 8 mg enhances vision and extends injection intervals for nAMD and DME patients, reducing treatment burden significantly.
Panelists discuss how the GALAXI trials’ limitations include exclusion of patients with penetrating/stricturing disease and perianal fistulizing disease and pediatric populations, while emphasizing key takeaways for different stakeholders: Patients can expect strong symptomatic relief with endoscopic healing and excellent safety, providers gain a rigorously-tested first-line treatment option with evidence-based positioning in treatment algorithms and payers should recognize the high-value therapy with potential long-term cost savings through durable remission and reduced disease complications.
An expert discusses how underutilization of combination lipid-lowering therapies stems from overly complex guidelines, primary care providers managing multiple chronic diseases simultaneously, cost and insurance coverage concerns, unfamiliarity with newer medications, and systemic health care barriers. He notes that these issues are particularly problematic when 50% of patients who experienced a heart attack are not even receiving foundational statin therapy 6 months post event.
Alfredo A. Sadun, M.D., Ph.D., discusses two applications of AI in ophthalmology where AI far exceeds what a human ophthalmologist can do.
Medical specialities, such as ophthalmology, that rely on imaging are among the early and most successful adoptors of artificial intelligenc
The AAO 2025 meeting ends Monday afternoon with presentations on possible ocular side effects from the GLP-1s.
An expert discusses how the lack of transparency in medication pricing creates a "black box" between actual drug costs and patient expenses, negatively affecting both patient care and the health care system's ability to provide effective vitiligo treatments.
In ER+/HER2- metastatic breast cancer, treatment in later lines focuses on extending disease control while managing resistance and maintaining quality of life.
An expert discusses how chronic kidney disease (CKD), often underdiagnosed and poorly recognized, is intricately linked with cardiovascular and metabolic conditions, emphasizing the urgent need for earlier detection, integrated care across specialties, and a more holistic approach to reduce the widespread impact on both heart and kidney health.
The EMERALD trial evaluated elacestrant, an oral SERD, as a potential new standard for patients with ER+/HER2– advanced breast cancer resistant to prior endocrine therapies.
In this interview, Steven Buslovich, M.D., CMD, MS, chief medical officer of senior care at PointClickCare, explains the growing role of AI in healthcare, particularly in managing patient transitions between care settings.
In this video interview, Francesca Bridge, MBBS, neurologist at Alfred Health in Melbourne, Australia, and Ph.D. candidate at Monash University, shares why the results of her latest research were reassuring, but surprising.
An expert discusses how treatment decisions must balance short-term burden with long-term benefits while avoiding protocol-driven step therapy requirements, as future comparative effectiveness trials and real-world evidence will better inform individualized patient care strategies.
Panelists discuss how guselkumab demonstrated a very reassuring safety profile with no new safety signals or unexpected adverse events compared with placebo and consistent with safety data from other disease indications, requiring no different monitoring protocols than standard care for Crohn’s disease patients on advanced therapies, while emphasizing that uncontrolled disease itself represents the biggest safety concern.
Panelists discuss how the GALAXI trial results demonstrated guselkumab’s durability, efficacy, rapid onset and clean safety profile with superiority over ustekinumab across most objective end points, including endoscopic response and deep remission. The clinical and endoscopic end points align with STRIDE-2 treatment targets and translate to meaningful patient outcomes, including symptom resolution and reduced future hospitalizations, surgeries and disease flares.
An expert discusses how nonstatin therapies serve as essential tools when patients can’t tolerate statins or need additional LDL cholesterol-lowering agents. These include ezetimibe (a cholesterol absorption inhibitor), bempedoic acid (a liver-specific prodrug) and PCSK9-interfering therapies (both injectable monoclonal antibodies and inclisiran), with treatment selection based on patient comorbidities, cardiovascular risk level and specific LDL cholesterol targets.
Some menopause symptoms may be mistaken for multiple sclerosis symptoms in older women, new research finds.
An expert discusses how insurance coverage barriers for Janus kinase (JAK) inhibitors in vitiligo treatment can be overcome by demonstrating medical necessity, especially for visible areas such as the face and hands, while emphasizing the cultural and social stigma that makes treatment essential rather than cosmetic.
An expert discusses the growing burden of atherosclerotic cardiovascular disease (ASCVD) in the U.S., emphasizing the importance of prevention through lifestyle modification and risk factor management while highlighting the need for proactive public health strategies as prevalence continues to rise.
Panelists discuss how bimekizumab represents a valuable addition to the psoriatic arthritis treatment armamentarium, given its novel dual mechanism, ability to address multiple disease domains and potential to benefit patients who have lost response to other biologics, reducing healthcare burden and improving societal economic outcomes.
Panelists discuss how the GALAXI trials enrolled a broadly generalizable population of adults with moderate to severe Crohn’s disease (CDAI 220-450) requiring objective evidence of active inflammation, including both bio-naive and bio-experienced patients with approximately 40% to 50% having previously failed advanced therapies, although patients previously exposed to ustekinumab or other p19 inhibitors were excluded due to the active comparator design.
An expert discusses how long-term durability data at one to two years, rather than short-term three-month responses, provides greater confidence in treatment selection and influences formulary decisions based on comparative efficacy and toxicity profiles.
Panelists discuss how the GALAXI-2 and GALAXI-3 trials represented a landmark study design for Crohn’s disease research through their rigorous triple-dummy active comparator methodology, treat-through model without rerandomization, inclusion of both bio-naive and bio-experienced patients, composite primary end points measured at individual patient levels, and the unique ability to conduct pooled analyses comparing guselkumab directly with ustekinumab as an active comparator.
